WO1997017460A1 - Procede de production de phosphatidylserines comportant un acide gras non sature polybasique en tant que chaine laterale - Google Patents
Procede de production de phosphatidylserines comportant un acide gras non sature polybasique en tant que chaine laterale Download PDFInfo
- Publication number
- WO1997017460A1 WO1997017460A1 PCT/JP1996/003237 JP9603237W WO9717460A1 WO 1997017460 A1 WO1997017460 A1 WO 1997017460A1 JP 9603237 W JP9603237 W JP 9603237W WO 9717460 A1 WO9717460 A1 WO 9717460A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- acid
- lecithin
- polyunsaturated fatty
- side chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6481—Phosphoglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
Definitions
- the present invention relates to a method for producing a phosphatidylserine having a polyunsaturated fatty acid in a side chain, and more specifically, it is effective for the prevention and treatment of dementia such as Parkinson's disease and Alzheimer's disease,
- the present invention relates to a method for producing an oil / fat composition having a cerebral function-improving effect of increasing resistance to cerebral dysfunction and further enhancing learning effect.
- Zanotti's Fortune K (A. Zanotti et al., Psychopharmacology Berl., Vol. 99, p. 316, 1989) also found that phosphatidylserine, which was similarly extracted from the brain of the sword, had reduced memory. It is stated that oral administration to aged rats for 12 weeks improved the behavior of the aged rats.
- phosphatidyl derived from cereal brain shows an effect of increasing glucose concentration in the brain.
- Lucerin has the effect of improving rat brain function. Therefore, the degree of increase in glucose concentration in the brain is considered to be an important index when selecting a substance having an effect of improving brain function.
- a substance that combines polyunsaturated fatty acids and phosphatidylserine in the hope of an additive effect or a synergistic effect of both substances has an effect of activating protein kinase C (PKC).
- PKC protein kinase C
- a phosphatidylserine derivative having a specific fatty acid at position 2 of the glycerol skeleton has been reported.
- JP-A-6-2791311 Japanese Unexamined Patent Publication: JP-A-6-2791311. This gazette presupposes that phosphatidylserine derived from human brain, which has a clinical brain improving effect, is a mixture composed of various fatty acids, and the effect when the constituent fatty acids are specified is not known.
- the 1st position is a saturated fatty acid (14-18 carbon atoms) and the 2nd position is linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid (DHA) It is stated that protein kinase C activation was specifically observed when
- the method for producing glycerol derivatives disclosed in this patent publication is a method of separation from natural products, a chemical synthesis method or a method of treating with phospholipase C, which is industrially advantageous and suitable for food applications. This is hard to say. Disclosure of the invention
- the main object of the present invention is to solve the above-mentioned problems and to provide a method for producing phosphatidylserine having a polyunsaturated fatty acid in a side chain in a relatively simple manner, that is, with a small number of steps. is there.
- Another object of the present invention is to provide a method for easily producing phosphatidylserine having a fatty acid composition of n-3 or n-6 polyunsaturated fatty acids.
- a method for producing phosphatidylserine having a polyunsaturated fatty acid in a side chain comprises using natural lecithin containing a polyunsaturated fatty acid as a side chain fatty acid as a substrate, It is characterized by the action of phospholipase D on natural lecithin in the presence of serine.
- it is composed of n-3 type ⁇ -linolenic acid, eicosapenic acid, docosahexanoic acid, and ⁇ -6 type linoleic acid, perinolenic acid, and arachidonic acid.
- Natural lecithin containing at least one polyunsaturated fatty acid selected from the group is used for the substrate.
- lecithin extracted from the head tissue of a marine fish is used as the substrate.
- yolk lecithin extracted from eggs laid by female chickens fed fish oil and / or vegetable oil containing polyunsaturated fatty acids is used for the substrate.
- phosphatidylcholine fractionated and concentrated from the natural lecithin is used as the substrate.
- phosphatidylethanolamine fractionated and concentrated from the natural lecithin is used as the substrate.
- the basic philosophy of the present invention is to use a natural lecithin having a polyunsaturated fatty acid as a side chain at position 2 (/ 3 position) as a substrate for a phosphatidyl group transfer reaction so that a polyunsaturated fatty acid can be When the phosphatidyl L-serine in the side chain is obtained It relies on this new knowledge. According to this new finding, phosphatidylserine rich in polyunsaturated fatty acids can be easily produced by a simple one-step phosphatidyl group transfer reaction.
- the phosphatidylserine thus produced is rich in polyunsaturated fatty acids, the phosphatidylserine and polyunsaturated fatty acids exhibit the respective effects of additively or synergistically. It can be said that it is a brain function improving substance.
- natural lecithin having a polyunsaturated fatty acid as a side chain fatty acid is used as a substrate for a phosphatidyl group transfer reaction, and phospholipase D is added to this natural lecithin in the presence of serine.
- phosphatidylserine having a polyunsaturated fatty acid in a side chain is obtained.
- Particularly preferred natural lecithins for use in the present invention are the n-3 based ⁇ -linolenic acid, eicosapentaenoic acid ( ⁇ ⁇ ⁇ ), docosahexaenoic acid (DHA), and the ⁇ -6 based linoleic acid , ⁇ -linolenic acid and arachidonic acid, which contain at least one kind of polyunsaturated fatty acid.
- Such polyunsaturated fatty acids have learning ability improving effects and various physiologically active effects. Therefore, phosphatidylserine obtained from such natural lecithin also contains these polyunsaturated fatty acids, and thus has a learning ability improving effect and various physiologically active effects.
- the phosphatidylserine produced according to the present invention exerts the synergistic or synergistic effect of improving the brain function of phosphatidylserine itself and the above-mentioned effects of the polyunsaturated fatty acid contained in the molecule. It is an excellent brain function improving substance.
- a one-step phosphatidyl group transfer reaction using a natural lecithin containing a polyunsaturated fatty acid as a substrate without a complicated multi-step reaction or a chemical synthesis method as in the past. Phosphatidylserine having a polyunsaturated fatty acid in the side chain can be easily produced only by the step.
- a brain function-improving substance that exerts the effects of polyunsaturated fatty acid and phosphatidylserine additively or synergistically is industrially more advantageous than conventional methods, Suitable for It can be manufactured with safety.
- natural lecithin with a high content of polyunsaturated fatty acids in position 2 includes marine fish that contain a large amount of polyunsaturated fatty acids in body tissues, especially in head tissues, and specifically, tuna, bonito, ⁇ , and sardine.
- a method for obtaining egg yolk lecithin containing polyunsaturated fatty acids such as ⁇ -linolenic acid, ⁇ -linolenic acid, arachidonic acid, and docosahexaenoic acid involves the use of these polyunsaturated fatty acids.
- a simple method is to add fish oil and / or vegetable oils such as soybean oil, perilla oil, cottonseed oil, sesame oil, corn oil, and safflower oil to feed, and use chicken eggs produced by hens fed this feed. Since the egg yolk of the hen egg obtained from the female chicken fed and fed with the polyunsaturated fatty acid contains lecithin rich in polyunsaturated fatty acid, Extract yolk lecithin from
- these natural lecithins mainly contain a specific phospholipid, that is, phosphatidylcholine phosphatidylethanolamine, and sometimes further contain phosphatidylglycerol. Therefore, in addition to using these natural lecithins as such as reaction substrates, lecithin fractionated and concentrated in specific phospholipids, for example, phosphatidylcholine or phosphatidylethanolamine, can also be used as substrates for phosphatidyl group transfer reactions.
- the desired lecithin is selected from the various types of natural lecithin or fractionated and concentrated as described above, and phospholipase D is allowed to act on the desired lecithin in the presence of serine.
- phospholipase D is allowed to act on the desired lecithin in the presence of serine.
- phosphatidyl-L-serine was produced using DHA-containing egg yolk lecithin as a raw material.
- the egg yolk lecithin used here was extracted from the eggs of female nits fed and fed fish and vegetable oils containing polyunsaturated fatty acids, which are generally available on the market. is there.
- phosphatidyl-L-serine spot portion of the thin plate was removed, and the fatty acid fraction was further extracted from the extracted portion of the extracted portion by means of chromate-form chromatography by capillary column chromatography. I took it out. After praying for this fatty acid, it was confirmed that it contained about 13% of DHA (22 carbon atoms, 6 double bonds).
- DHA 22 carbon atoms, 6 double bonds
- this product contains about 13% DHA (C22: 6), about 3% linoleic acid (C18: 2), and arachidonic acid (C20: 4) was contained in about 6%.
- phosphatidyl-L-serine was produced using lecithin obtained from the head muscle of yellowfin tuna as a raw material.
- the head of yellowfin tuna (about 1.6 kg) was pulverized and freeze-dried to obtain a dry powder.
- a mixed solvent of isopropanol: hexane: water 1: 20: 3 was added to extract a lipid fraction, and the extract was concentrated to dryness under reduced pressure.
- Acetone was added to about 18 g of the obtained dried lipid, and the mixture was cooled on ice, and the resulting precipitate was dried to obtain about 30 Omg of phospholipid.
- Phosphatidyl-L-serine was produced using the phospholipid obtained by the above operation. That is, 400 L of a solution containing 1 O Omg of phospholipid, 2 mL of ethyl acetate, and 120 mg of L-serine, and 15 units of phospholipase D (trade name: phospholipase D—Y1, Yakult Honsha, Japan) A 300 L enzyme aqueous solution was sealed in a vial bottle under a nitrogen stream, and the mixture was incubated with shaking and stirring at 50 ° C for 10 hours to perform a phosphatidyl group transfer reaction.
- Example 2 the phosphatidyl-L-serine spot on the thin layer
- the stationary phase was removed, and the fatty acid fraction was further fractionated from the extracted fraction of the contacted portion with the form of black mouth by capillary column chromatography.
- this fatty acid was analyzed, as shown in Table 1 below, the content of DHA (C22: 6) was about 45%, and the content of EPA (C20: 5) was about 4%.
- phosphatidyl-L-serine having a high DHA content was obtained by a phosphatidyl group transfer reaction using phospholipase D using lecithin extracted from the head of yellowfin tuna as a substrate. .
- phosphatidyl-L-serine was produced using lecithin obtained from the head muscle of SBT as a raw material.
- the lipid fraction was extracted by adding the mixed solvent of 3, and the extract was concentrated to dryness under reduced pressure. Acetone was added to about 1 Og of the obtained dried lipid, and the mixture was cooled on ice. The resulting precipitate was dried to obtain about 25 Omg of phospholipid.
- Phosphatidyl-L-serine was produced using the phospholipid obtained by the above operation. That is, 400 L of a suspension solution containing 10 Omg of phospholipid, 2 m of ethyl acetate, and 120 mg of L-serine, and phospholipase D (trade name: phospholipase D—Y 1, Yakult Honsha, Japan) 150 units and CaC 300 including 1 2 5111
- the L enzyme aqueous solution was sealed in a vial bottle under a nitrogen stream, and this was incubated at 50 ° C for 10 hours with vigorous stirring to carry out a phosphatidyl group transfer reaction. After the reaction was completed, the paste portion cooled and precipitated in the vial was analyzed for phospholipids by thin-layer chromatography and image analysis in the same manner as in Example 1. As a result, it was found that 82% of phosphatidyl-L-serine was formed in the phospholipid. In the same manner as in Example 1, the stationary phase at the spot portion of phosphatidyl-L-serine on the thin layer was picked up. The fatty acid fraction was collected by immunography.
- phosphatidyl-L-serine was produced using lecithin obtained from bonito head muscle as a raw material.
- Phosphatidyl-L-serine was produced using the phospholipid obtained by the above operation. That is, 400 wL of a solution containing 1 OOmg of phosphorescent substance, 2mL of ethyl acetate, and 120mg of L-serine, and 300jL of phospholipase D (trade name: Phospholipase D-Y1, Yakult Honsha, Japan) 15 units The enzyme aqueous solution was sealed in a vial under a nitrogen stream, and the mixture was incubated at 50 ° C. for 10 hours while shaking and stirring to carry out a phosphatidyl group transfer reaction.
- Example 2 In the same manner as in Example 1, the stationary phase at the spot portion of phosphatidyl L-serine on the thin layer was removed, and the extracted portion was extracted from the extract with a black hole form.
- the fatty acid fraction was separated by chromatography. When this fatty acid was analyzed, as shown in Table 1 below, the content of DHA (C22: 6) was about 45%, and the content of EPA (C20: 5) was about 8%.
- Example 4 lecithin extracted from the head of southern bluefin tuna was used as a substrate, and phosphatidyl-L-serine containing DHA and EPA was obtained by a phosphatidyl group transfer reaction with phospholipase D. was completed.
- Table 1 below shows the content by type of fatty acid of phosphatidyl L-serine obtained in each example described above.
- Example 1 Example 2 Example 3 Example 4
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/860,739 US5965413A (en) | 1995-11-08 | 1996-11-06 | Process for producing phosphatidylserines having long chain unsaturated fatty acid as side chain |
DE69626107T DE69626107T2 (de) | 1995-11-08 | 1996-11-06 | Verfahren zur herstellung von phosphatidylserinen mit polybasischer, ungesättigter fettsäure als seitenkette |
EP96937503A EP0819760B1 (en) | 1995-11-08 | 1996-11-06 | Process for producing phosphatidylserines having polybasic unsaturated fatty acid as side chain |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP31370795A JP3791951B2 (ja) | 1995-11-08 | 1995-11-08 | 多価不飽和脂肪酸含有ホスファチジルセリンを含む油脂組成物の製造方法 |
JP7/313707 | 1995-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997017460A1 true WO1997017460A1 (fr) | 1997-05-15 |
Family
ID=18044556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/003237 WO1997017460A1 (fr) | 1995-11-08 | 1996-11-06 | Procede de production de phosphatidylserines comportant un acide gras non sature polybasique en tant que chaine laterale |
Country Status (6)
Country | Link |
---|---|
US (1) | US5965413A (ja) |
EP (1) | EP0819760B1 (ja) |
JP (1) | JP3791951B2 (ja) |
CN (1) | CN1103818C (ja) |
DE (1) | DE69626107T2 (ja) |
WO (1) | WO1997017460A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1311929B1 (it) | 1999-04-28 | 2002-03-20 | Chemi Spa | Procedimento per la preparazione di fosfatidilserine. |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
JP4298902B2 (ja) * | 2000-08-09 | 2009-07-22 | 株式会社ヤクルト本社 | リン脂質の製造法 |
JP2004520845A (ja) * | 2001-03-26 | 2004-07-15 | ギヴエンテイス・ゲゼルシヤフト・ミット・ベシュレンクテル・ハフツング | 認知能力を高めるための食品 |
KR100442538B1 (ko) * | 2001-05-07 | 2004-07-30 | 주식회사 두산 | 유기용매에서 포스파티딜세린 및 리조포스파티딜세린의제조방법 |
JP2004002663A (ja) * | 2002-03-29 | 2004-01-08 | Shizuoka Prefecture | 魚類の内臓から多価不飽和脂肪酸を構成成分とするリン脂質を含む脂質組成物を抽出するための方法、その方法に適用可能な魚類の内臓の保存方法、及びその方法により抽出した脂質組成物 |
US7014631B2 (en) * | 2002-04-12 | 2006-03-21 | 3M Innovative Properties Company | Elastic closure tab |
KR20030086128A (ko) * | 2002-05-03 | 2003-11-07 | 주식회사 두산 | 효소 및 세린의 재사용을 포함하는 포스파티딜세린 및리소포스파티딜세린의 제조방법 |
KR20040069438A (ko) * | 2003-01-29 | 2004-08-06 | 주식회사 두산 | 유기용매 혼합물을 이용한 변형 레시틴의 제조방법 |
US6878532B1 (en) | 2003-04-28 | 2005-04-12 | Sioux Biochemical, Inc. | Method of producing phosphatidylserine |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
US20050130937A1 (en) | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
US20050158835A1 (en) * | 2004-01-21 | 2005-07-21 | Su Chen | Preparation of highly polyunsaturated fatty acid-containing phosphatidylserine and phosphatidic acid |
JP4650746B2 (ja) * | 2004-03-18 | 2011-03-16 | ナガセケムテックス株式会社 | 酵素の除去方法および該方法を用いるリン脂質の塩基転移または加水分解方法 |
WO2007021735A2 (en) * | 2005-08-10 | 2007-02-22 | William Llewellyn | Use of phospholipid arachidonic acids for increasing muscle mass in humans |
JP2007129973A (ja) * | 2005-11-11 | 2007-05-31 | Univ Of Miyazaki | 不飽和脂肪酸含有リン脂質の製造方法 |
JP5041790B2 (ja) * | 2006-11-10 | 2012-10-03 | 日本水産株式会社 | 多価不飽和脂肪酸を構成要素とするホスファチジルセリンの製造方法 |
EP2100897A1 (en) * | 2008-01-30 | 2009-09-16 | BNLfood Investments SARL | Lecithin based composition and its use in food |
JP2009256331A (ja) * | 2008-03-25 | 2009-11-05 | Nagase Chemtex Corp | 高尿酸血症、又は痛風の予防、改善、又は治療剤 |
US8399432B2 (en) * | 2009-10-27 | 2013-03-19 | Lipogen Ltd. | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
CN101701229B (zh) * | 2009-11-17 | 2012-08-29 | 广州海莎生物科技有限公司 | 一种制取质构磷脂和卵磷脂的方法 |
US20110223246A1 (en) * | 2010-03-10 | 2011-09-15 | Joar Opheim | Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source |
CN101818179A (zh) * | 2010-04-28 | 2010-09-01 | 大连理工大学 | 一种制备富含多不饱和脂肪酸的磷脂酰丝氨酸的方法 |
WO2012043481A1 (ja) | 2010-09-30 | 2012-04-05 | 国立大学法人東京海洋大学 | 2-アシル-リゾホスファチジルセリン含有組成物及びその製造方法 |
CN102439125B (zh) * | 2010-12-03 | 2014-04-30 | 上海赢贝生物技术有限公司 | 一种制备富含多不饱和双键脂肪酰基的磷脂酰丝氨酸的高品质南极磷虾油的方法 |
CN102485899A (zh) * | 2010-12-03 | 2012-06-06 | 张永志 | 一种制备富含多不饱和双键脂肪酰基的磷脂酰丝氨酸的高品质南极磷虾油的方法 |
CN102277394B (zh) * | 2011-07-22 | 2013-04-17 | 天津科技大学 | 一种细胞表面展示磷脂酶d酵母全细胞催化剂催化制备磷脂酰丝氨酸的方法 |
WO2013086327A1 (en) * | 2011-12-08 | 2013-06-13 | Abbott Laboratories | Nutritional compositions comprising curcumin and phosphatidylserine-docosahexaenoic acid for improving cognition |
EP2862937A4 (en) | 2012-06-13 | 2016-01-27 | Kaneka Corp | METHOD FOR PRODUCING PHOSPHOLIPID-CONTAINING COMPOSITION AND COMPOSITION CONTAINING PHOSPHOLIPID |
CN103351403A (zh) * | 2013-07-24 | 2013-10-16 | 华东师范大学 | 一种磷脂酰丝氨酸的合成方法 |
CN104327114A (zh) * | 2014-11-06 | 2015-02-04 | 江南大学 | 一种磷脂酰丝氨酸的制备方法 |
CN107164397A (zh) * | 2017-04-28 | 2017-09-15 | 江南大学 | 一种磷脂酶d的基因挖掘及其应用方法 |
CN107318983A (zh) * | 2017-06-14 | 2017-11-07 | 芜湖福民生物药业股份有限公司 | 含磷脂酰丝氨酸的奶粉及其制备方法 |
CN107149146A (zh) * | 2017-06-14 | 2017-09-12 | 芜湖福民生物药业股份有限公司 | 含磷脂酰丝氨酸的含片及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63245684A (ja) * | 1987-03-31 | 1988-10-12 | Japanese Res & Dev Assoc Bio Reactor Syst Food Ind | ホスフアチジン酸誘導体の製造法 |
JPH0279990A (ja) * | 1988-09-16 | 1990-03-20 | Nippon Oil & Fats Co Ltd | ホスファチジルセリンの製造方法 |
JPH05336983A (ja) * | 1992-06-04 | 1993-12-21 | Kanegafuchi Chem Ind Co Ltd | リン脂質の生産方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0716426B2 (ja) * | 1986-08-01 | 1995-03-01 | 日本油脂株式会社 | 酵素によるリン脂質の製造方法 |
JPS6336791A (ja) * | 1986-08-01 | 1988-02-17 | Nippon Oil & Fats Co Ltd | 酵素によるリン脂質の製造方法 |
JPH0761276B2 (ja) * | 1986-11-14 | 1995-07-05 | 名糖産業株式会社 | 酵素法リン脂質−d−セリン誘導体の製造法 |
US5117034A (en) * | 1989-10-24 | 1992-05-26 | Fuji Photo Film Co., Ltd. | Phosphatidylserine derivatives |
JP3467794B2 (ja) * | 1993-03-09 | 2003-11-17 | 日本油脂株式会社 | 学習能向上剤 |
JPH06279311A (ja) * | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼcアイソザイムの活性化剤 |
US5540935A (en) * | 1993-12-06 | 1996-07-30 | Nof Corporation | Reactive vesicle and functional substance-fixed vesicle |
US5700668A (en) * | 1995-12-08 | 1997-12-23 | Italfarmaco Sud S.P.A. | Process for the industrial preparation of phosphatidylserine |
-
1995
- 1995-11-08 JP JP31370795A patent/JP3791951B2/ja not_active Expired - Lifetime
-
1996
- 1996-11-06 EP EP96937503A patent/EP0819760B1/en not_active Expired - Lifetime
- 1996-11-06 CN CN96192358A patent/CN1103818C/zh not_active Expired - Lifetime
- 1996-11-06 US US08/860,739 patent/US5965413A/en not_active Expired - Lifetime
- 1996-11-06 DE DE69626107T patent/DE69626107T2/de not_active Expired - Lifetime
- 1996-11-06 WO PCT/JP1996/003237 patent/WO1997017460A1/ja active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63245684A (ja) * | 1987-03-31 | 1988-10-12 | Japanese Res & Dev Assoc Bio Reactor Syst Food Ind | ホスフアチジン酸誘導体の製造法 |
JPH0279990A (ja) * | 1988-09-16 | 1990-03-20 | Nippon Oil & Fats Co Ltd | ホスファチジルセリンの製造方法 |
JPH05336983A (ja) * | 1992-06-04 | 1993-12-21 | Kanegafuchi Chem Ind Co Ltd | リン脂質の生産方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0819760A1 (en) | 1998-01-21 |
DE69626107T2 (de) | 2004-01-22 |
DE69626107D1 (de) | 2003-03-13 |
JPH09121879A (ja) | 1997-05-13 |
EP0819760A4 (en) | 1998-09-30 |
EP0819760B1 (en) | 2003-02-05 |
CN1177381A (zh) | 1998-03-25 |
JP3791951B2 (ja) | 2006-06-28 |
CN1103818C (zh) | 2003-03-26 |
US5965413A (en) | 1999-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997017460A1 (fr) | Procede de production de phosphatidylserines comportant un acide gras non sature polybasique en tant que chaine laterale | |
AU2011200414B2 (en) | Process for Producing Phospholipid Containing Long Chain Polyunsaturated Fatty Acid as Constituent Thereof and Utilization of the Same | |
US11400105B2 (en) | Anti-inflammatory properties of marine lipid compositions | |
US8052992B2 (en) | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions | |
US11065267B2 (en) | Lysophosphatidylcholine compositions | |
JP3053537B2 (ja) | 脳機能改善剤 | |
IL176054A (en) | Oil or fat compositions containing phospholipids and long-chain polyunsaturated fatty acid supplying compound and food using the same | |
AU2007212967A1 (en) | Microbial fermentation-based production of phospholipids containing long-chain polyunsaturated fatty acids as their constituents | |
JP2001186898A (ja) | 多価不飽和脂肪酸残基をもつホスファチジルセリンの製造法 | |
Yurkowski et al. | The molecular species of mucosal phosphatidyl cholines from the small intestine of normal and essential fatty acid-deficient rats | |
JP2001245687A (ja) | n−4系及び/又はn−7系高度不飽和脂肪酸を含有する脂質及びその製造方法 | |
JP2006340733A (ja) | n−4系及び/又はn−7系高度不飽和脂肪酸を含有する脂質及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96192358.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08860739 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996937503 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996937503 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996937503 Country of ref document: EP |